Biotech Values

[DewDiligence]

Does the approval of m-enoxaparin now negate the need to do a capital raise for the foreseeable future?

It depends on: i) what MNTA wants to do about M118; and ii) the share price.

As of today, MNTA has about $65M in cash, i.e. $81.7M less whatever has been burned since 3/31/10 (#msg-49928065). That’s enough cash to get by for all of 2010 and most or all of 2011, so MNTA certainly doesn’t need to do anything rash. On the other hand, if MNTA sees an opportunity to raise cash on attractive terms in the near future, they probably will.